Markus Mitterhauser is the Director of the Ludwig Boltzmann Institute Applied Diagnostics and leading the program line Applied Translational Research as key researcher.

Other current affiliations include:

• Head of the Experimental Nuclear Medicine (μPET/SPECT/CT, autoradiography, binding studies, metabolite studies and biodistribution experiments) – currently on leave.
• Head of the Radiopharmacy of the General Hospital of Vienna, the radiopharmaceutical working group of the Austrian Society of Nuclear Medicine
• National radiopharmacy advisor of the EANM (European Association of Nuclear Medicine)

He studied Pharmacy at the University of Vienna, Austria. After several research visits to the Karolinska Institute, Stockholm, to the Chinese University of Hong Kong and the Service Hospitalier Frederic Joliot in Orsay, France, he finished his PhD at the University of Vienna and completed the postgraduate diploma course in radiopharmaceutical chemistry/radiopharmacy at the ETH Zurich. In addition, he holds the certificate for approved hospital pharmacists (aHPh). He received his Habilitation in Radiopharmacy at the Medical University of Vienna in 2006. Since 2012, he has been appointed as Visiting Professor for Radiopharmacy and Experimental Nuclear Medicine at the University of Vienna.

Research interests include the design, development and preclinical evaluation of new PET and SPECT-tracers.

Markus Mitterhauser won the first THP award for basic scientists in nuclear medicine (2003) and gives lectures at the University of Vienna, at the Medical University of Vienna and at the Advanced Technical College of Wiener Neustadt.